Plasma levels of ADMA, the most potent endogenous competitive inhibitor of NOs, represents an indicator of endothelial dysfunction and a predictor of cardiovascular mortality. The effectiveness of EPA and DHA in reducing mortality for CV fatal events has been extensively documented. Despite this, their mechanism of action remains almost unclear. The aim of the study was to verify the effect of EPA and DHA on ADMA plasma levels. We measured ADMA in the plasma of aged SHR (18 month old) treated with EPA and DHA (1 g/Kg/day; EPA-DHA) for 8 weeks and in the plasma of olive oil placebo treated animals (OLIVE). Our results show that OLIVE had high plasma levels of ADMA (1365,5 ± 399,1 pmol/ml). In EPA-DHA ADMA levels were significantly lowered (587 ± 113 pmol/ml). In parallel, in EPA-DHA animals, higher NOx levels than in OLIVE were found. No differences between goups were found for creatinine and homocytseine plasma levels, and in renal DDHA activity as well. These results show for the first time that EPA and DHA have the potential to reduce the concentration of this CV risk factor.

Chronic treatment with omega3-PUFA decreases plasma concentration of asymmetric dimethyl arginine (ADMA) in aged spontaneously hypertensive rat (SHR) / L. Raimondi; M. Lodovici; F. Guglielmi; L. Sartiani; P. De Paoli P; R. Pirisino; E. Cerbai; A. Mugelli. - In: NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY. - ISSN 0028-1298. - STAMPA. - 69:(2004), pp. 37-37. ((Intervento presentato al convegno Italian Pharmacol Soc; Dutch Pharmacol Soc.

Chronic treatment with omega3-PUFA decreases plasma concentration of asymmetric dimethyl arginine (ADMA) in aged spontaneously hypertensive rat (SHR).

RAIMONDI, LAURA;LODOVICI, MAURA;SARTIANI, LAURA;CERBAI, ELISABETTA;MUGELLI, ALESSANDRO
2004

Abstract

Plasma levels of ADMA, the most potent endogenous competitive inhibitor of NOs, represents an indicator of endothelial dysfunction and a predictor of cardiovascular mortality. The effectiveness of EPA and DHA in reducing mortality for CV fatal events has been extensively documented. Despite this, their mechanism of action remains almost unclear. The aim of the study was to verify the effect of EPA and DHA on ADMA plasma levels. We measured ADMA in the plasma of aged SHR (18 month old) treated with EPA and DHA (1 g/Kg/day; EPA-DHA) for 8 weeks and in the plasma of olive oil placebo treated animals (OLIVE). Our results show that OLIVE had high plasma levels of ADMA (1365,5 ± 399,1 pmol/ml). In EPA-DHA ADMA levels were significantly lowered (587 ± 113 pmol/ml). In parallel, in EPA-DHA animals, higher NOx levels than in OLIVE were found. No differences between goups were found for creatinine and homocytseine plasma levels, and in renal DDHA activity as well. These results show for the first time that EPA and DHA have the potential to reduce the concentration of this CV risk factor.
L. Raimondi; M. Lodovici; F. Guglielmi; L. Sartiani; P. De Paoli P; R. Pirisino; E. Cerbai; A. Mugelli
File in questo prodotto:
File Dimensione Formato  
Raimondi_NSAPharm_2004.pdf

Accesso chiuso

Tipologia: Altro
Licenza: DRM non definito
Dimensione 32.07 kB
Formato Adobe PDF
32.07 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/771948
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact